Competition for gastrointestinal drugs is fierce... Monthly prescriptions for ‘Zacubo’ exceed KRW 10 billion for the first time
Jeil Pharmaceutical's Jacubo recorded 10.3 billion won in outpatient prescriptions in October this year... View of Padoprajan and Bosinti
Quick Look
- Jeil Pharmaceutical's P-CAB treatment Jacubo surpassed KRW 10 billion in monthly prescriptions for the first time in October this year with KRW 10.3 billion in outpatient prescriptions.
- In the domestic P-CAB market, competition is expected to intensify with the addition of Daewon Pharmaceutical's Padoprazan and Takeda Pharmaceutical's Bosinti in a three-way battle between K-Cap, Jacubo, and Pexuclu.
AI-generated summary
Why It Matters
The domestic P-CAB treatment market is a new addition to the gastric acid inhibitor market, which was dominated by PPI-based treatments. Domestic sales, which were around 100 billion won in 2021, are expected to exceed 400 billion won this year. Currently, K-Cap, Jacubo, and Pexuclu are engaged in a three-way battle.
Amid fierce domestic potassium-competitive gastric acid secretion inhibitor (P-CAB) competition, Jeil Pharmaceutical's [271980] 'Zacubo' exceeded 10 billion won in monthly prescriptions for the first time.
Jeil Pharmaceutical announced on the 10th that the amount of outpatient prescriptions for Jacubo in October of this year was 10.3 billion won, citing data from UBIST, a pharmaceutical market research firm.
Jacubo was developed by Onconic Therapeutics [476060], a subsidiary of Jeil Pharmaceutical, and was released in 2024.
Since its launch, Jeil Pharmaceutical has actively carried out sales and marketing activities with Dong-A ST [170900], and in January of this year, it additionally released an orally disintegrating tablet with improved ease of administration.
Jeil Pharmaceutical is conducting clinical trials to expand the indications for Jacubo to include non-erosive gastroesophageal reflux disease and maintenance therapy for erosive gastroesophageal reflux disease.
The P-CAB class treatment is a new drug that has appeared in the gastric acid suppressant market, which was dominated by the proton pump inhibitor (PPI) class treatment.
Domestic sales of P-CAB series treatments were approximately KRW 100 billion in 2021, but are expected to exceed KRW 400 billion this year.
In the domestic P-CAB treatment market, there has been a three-way battle between HK Innoen [195940]'s 'K-Cap', Jacubo, and Daewoong Pharmaceutical's [069620]'s 'Pexuclu', but competition is expected to intensify as latecomers are expected to participate.
Daewon Pharmaceutical [003220] confirmed the effectiveness of 'Padoprazan' in phase 3 clinical trials and plans to apply for product approval to the Ministry of Food and Drug Safety within the year, and Takeda Pharmaceutical of Japan is also planning to launch 'Bosinti' in Korea.
What to Watch
AI outlook — possibilities, not facts
Daewon Pharmaceutical will apply for Fadoprazan product approval to the Ministry of Food and Drug Safety within the year.
Very likely · Within months
Japan's Takeda Pharmaceutical will launch Bosinti in Korea.
Very likely · Within months
Sales of the domestic P-CAB treatment market will exceed 400 billion won this year.
Likely · Within months
Open Questions
- When will Padoprajan apply for product approval and what is the expected release schedule?
- What is Bosinti’s expected domestic release date?
- What are the clinical results and schedule for Jacubo’s indication expansion?
- What are the changes in each company's market share outlook after the addition of new competitors?
![[Featured stock] Airline stocks soar as international oil prices plunge… Korean Air 9% range↑](/api/img?u=https%3A%2F%2Fimg.yna.co.kr%2Fphoto%2Fyna%2FYH%2F2026%2F09%2F08%2FPYH2026090817960001303_P2.jpg&w=320&q=72&f=webp)
